Nanobiotix: surrounded after completion of a study

(CercleFinance.com) - Nanobiotix jumps 10% following the completion of the dose escalation and expansion portions of the Phase 1 study evaluating NBTXR3 (JNJ-1900) activated by radiotherapy (RT) in locally advanced or borderline resectable pancreatic cancer (LAPC).


A median overall survival of 23 months after diagnosis was observed in 22 patients, and the investigators concluded that the encouraging results combined with a favorable safety profile warrant further evaluation in a randomized trial.

A protocol amendment has therefore been approved by the US FDA to launch a new cohort evaluating RT-activated NBTXR3 in combination with standard concomitant chemotherapy. Recruitment is underway.

Copyright (c) 2024 CercleFinance.com. All rights reserved.